Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Globus Medical Inc. Class A Common Stock (GMED) vs Msci Inc (MSCI) Price & Performance

Globus Medical Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Globus Medical Inc. Class A Common Stock vs Msci Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Msci Inc trades at $560.52 (market cap $41.29B). The key difference: Msci Inc is far larger — about 4× Globus Medical Inc. Class A Common Stock's market cap, and Msci Inc pays a 1.44% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Msci Inc for 83 Days on average.

GMEDMSCI
Market Cap
$10.25B$41.29B
Volume
1,108,124468,436
Sector
HealthFinancials
52-Week High
$96.82$643.83
52-Week Low
$58.33$511.84
Typical Hold Time
0 Days83 Days
Enterprise Value
$9.76B$47.46B
Dividend Yield
—1.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Globus Medical Inc. Class A Common Stock

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Msci Inc

MSCI trades at $560.52, down 1.32% today, with strong profitability (40.73% net margin) and consistent revenue growth from $2.2B in 2022 to $3.1B in 2025. Recent Q2 2026 earnings missed expectations at $4.94 EPS, but Q1 and Q4 2025 beat. Technicals show a bullish moving average signal with RSI at 59.48 neutral, while analyst consensus is strongly bullish with a $701.71 price target. The company maintains robust cash flow from operations of $1.6B in 2025.

Outlook remains positive driven by recurring revenue streams and market position, though high valuation (P/E 31.06) and debt levels ($4.51B long-term) pose risks. The upcoming Q3 2026 earnings on October 20, 2026, is a key catalyst. Investors should weigh strong fundamentals against premium pricing and macroeconomic sensitivity.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GMED
100% Buy0% Sell
Avg holding period · 0 Days
MSCI
5% Buy95% Sell
Avg holding period · 83 Days

Top news

Latest headlines on both assets

About Globus Medical Inc. Class A Common Stock

Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.

Read more on GMED →

About Msci Inc

MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.

Read more on MSCI →